EU regulators to review Sandoz’ Neulasta biosimilar
admin 30th October 2017 Uncategorised 0The European Medicines Agency has accepted for review Novartis unit Sandoz’ biosimilar of Amgen’s Neulasta.
More: EU regulators to review Sandoz’ Neulasta biosimilar
Source: News